Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal Cancer
Status:
Active, not recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
This is a single arm phase II study, in which 2 cycles of chemotherapy (5FU/CDDP) and
immunotherapy (durvalumab and tremelimumab) are administered every 3 weeks with concurrent
radiotherapy for inoperable locally advanced esophageal squamous cell carcinoma. Four weeks
after completion of CCRT combined with immunotherapy, 2 cycles of durvaluma and tremelimumab
will be administered every 4 weeks and thereafter durvalumab monotherapy Q4W will be
maintained until unacceptable toxicity or disease progression, or for maximum 2 years after
enrollment.